Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist, for Ananptys

 

• Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis
• Vanda expects to immediately begin preparing BLA and MAA applications for the US and EU
• Anaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supply
• Anaptys to receive a 10% royalty on global net sales of imsidolimab

https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-and-anaptys-announce-exclusive-global-license-agreement-for-vanda-to-develop-and-commercialize-imsidolimab-an-il-36r-antagonist-302366027.html